Khaitan, Debevoise, Platinum, JSA act on 3% acquisition by Capital International in Intas PharmaApril 5 2017
PE Firm Capital International has bought 3% stake in Intas Pharmaceuticals from ChrysCapital , for an estimated value of ₹690 crore ($107 million).
ChrysCapital will continue to hold 3% in Intas.
Capital International buys 3% stake in Intas Pharmaceuticals
Capital International - Khaitan & Co, Debevoise & Plimption; ChrysCapital - Platinum Partners; Intas Pharmaceuticals - J Sagar Associates
Partners/Heads . . .
You need to have an active subscription to view this content.
With a premium account you get:
- One year of unrestrcited access to previous interviews, columns and articles
- One year access to all archival material
- Access to all Bar & Bench reports